HAI Europe Office
Overtoom 60 (2)
1054 HK Amsterdam
The Netherlands
Telephone: + 31 20 683 3684

  • hai_africa
  • hai_asia
  • hai_global
  • ais_us

Trading Away Access to Medicines (Revisited) – New report from HAI Europe and Oxfam

A new report by HAI Europe and Oxfam has found that the European Commission is putting the interests of multinational drug companies above those of millions of people with no access to affordable life-saving medicines. The lack of a widely accessible treatment for Ebola, as well as the high price of Hep-C and cancer medicines, show that it's time for the Commission to rethink its trade and innovation policies. Also see our press release.

Investor-to-state dispute settlement in EU-US trade agreement risks access to affordable medicines

HAI Europe, along with several other European and American NGOs, publicly criticised the inclusion of 'investor-to-state dispute settlement' in the Transatlantic Trade and Investment Partnership (TTIP), warning that it will undermine public health policies of European Union Member States and severely jeopardise access to affordable medicines and public health protection. To learn more, read our joint press release and response to the European Commission's public consultation on the issue.

True commitment to transparency needed in EMA's policy on clinical trial data

HAI Europe continues pressing the European Medicines Agency not to backtrack on its commitments to clinical trial data transparency. The Agency is expected to formally adopt its new clinical trial data policy at its next management board meeting on 2 October. HAI Europe, along with other health and transparency advocates, as well as the European Ombudsman, have publicly expressed concerns that the Agency's policy will restrict public access to clinical trial data. Read more about it in our recent statement and blog post.

Read more about our commitment to transparency and 2014 Work Plan.